Trillium Therapeutics (TRIL) Falls on New Drug News

Trillium Therapeutics Inc. (NASDAQ:TRIL) shares leaped 8.2% to $14.71, on word the company has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies. Share volume was 77,000, compared to an all-day average of 91,000